title: [A strategy for second-line anti-Helicobacter pylori therapy in eradication-failure patients].
abstract: Although available H. pylori eradication regimens in Japan fail to cure 10-20% of patients, an optimal re-treatment therapy for eradication-failure patients has still not been established. Since patient compliance, bacterial resistance and genotypic differences in CYP2C19 influence the eradication rate, re-eradication therapy should be selected, taking them into consideration. In the West, meta-analysis of the second-line treatment of H. pylori infection showed therapies comprising ranitidine bismuth and two antimicrobials are very effective re-treatment therapies irrespective of factors influencing H. pylori eradication. However ranitidine bismuth is not available in Japan and re-eradication therapy consisting of PPI, amoxicillin and metronidazole have been often undertaken and have achieved high eradication rate, even including patients with metronidazole resistant H. pylori.
authors.affiliation: Department of Gastroenterology, Juntendo University School of Medicine.
authors.forename: Mariko
authors.initials: M
authors.lastname: Hojo
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Ohkusa
authors.forename: Hiroto
authors.initials: H
authors.lastname: Miwa
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Sato
mesh_terms: D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D017211:Treatment Failure